Michel Vounatsos
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Revvity Announces Earnings Call, Analysts Upgrade Rating. Revvity has announced that it will conduct an earnings call on November 3, 2026. Analysts have upgraded the stock’s rating, citing stronger fundamentals and a positive outlook. Today’s trading saw unusual volume and the price is near its support level of $110.97 with an RSI of 68.9, indicating a moderately overbought condition.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Transaction History
| ZLAB | ▲ Buy | Grant | 22,371 | $0 | 6/17/2026 | View on chart |
| RVTY | ▲ Buy | Grant | 1,015 | $0 | 5/7/2026 | View on chart |
| RVTY | ▲ Buy | Grant | 1,265 | $0 | 5/7/2026 | View on chart |
| ZLAB | ▲ Buy | Grant | 10,831 | $0 | 6/18/2025 | View on chart |
| RVTY | ▲ Buy | Grant | 1,074 | $0 | 4/30/2025 | View on chart |
| RVTY | ▲ Buy | Grant | 1,338 | $0 | 4/30/2025 | View on chart |
| ZLAB | ▲ Buy | Grant | 21,253 | $0 | 6/18/2024 | View on chart |
| RVTY | ▲ Buy | Grant | 977 | $0 | 5/1/2024 | View on chart |
| RVTY | ▲ Buy | Grant | 1,218 | $0 | 5/1/2024 | View on chart |
| RVTY | ▲ Buy | Grant | 783 | $0 | 5/15/2023 | View on chart |
| RVTY | ▲ Buy | Grant | 955 | $0 | 5/15/2023 | View on chart |
| ZLAB | ▲ Buy | Grant | 18,332 | $0 | 3/3/2023 | View on chart |
| RVTY | ▲ Buy | Grant | 610 | $0 | 5/6/2022 | View on chart |
| RVTY | ▲ Buy | Grant | 744 | $0 | 5/6/2022 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 6,191 | $0 | 2/18/2022 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 2,746 | $576K | 2/18/2022 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 4,321 | $0 | 2/12/2022 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 1,917 | $411K | 2/12/2022 | View on chart |
| BIIB | ▲ Buy | Option Exercise | 4,395 | $0 | 2/12/2022 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 1,950 | $418K | 2/12/2022 | View on chart |
| BIIB | ▼ Sell | Tax Withholding | 4,699 | $1.0M | 2/12/2022 | View on chart |
| BIIB | ▲ Buy | Grant | 10,594 | $0 | 1/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.